NEW YORK (GenomeWeb News) – SomaLogic, which is developing molecular diagnostic tests based on aptamers, and NEC have signed an agreement to explore business opportunities in the life science and healthcare markets, the firms said today.
In addition, NEC has made an equity investment in SomaLogic, though the amount of the investment and other financial terms were not disclosed.
Under the agreement, the two partners will develop and implement applications within NEC's cloud-based services platform "to enhance SomaLogic's products for life sciences research and diagnostics," they said in a joint statement.
Boulder, Colo.-based SomaLogic and NEC plan to integrate SomaLogic's Somamers technology with NEC's Bioprism information management system and other NEC data analysis tools, such as SVM+, a machine learning technique.
The companies did not specify what products would result from their collaboration, but said that customers for applications to be developed would include pharmaceutical firms, research laboratories, and practicing physicians, "with the eventual goal of expanding into personal healthcare services."
SomaLogic's Somamers technology uses aptamers, single-stranded DNA and RNA molecules that bind to specific target molecules with high affinity. According to the company, Somamers can quantify about 1,000 proteins from a drop of blood for the identification of disease-associated biomarkers.
The firm is in the process of developing a lung cancer test using its technology and plans to launch it as a lab-developed test next year.